Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Ueno T, et al. Among authors: hisamatsu k. Int J Clin Oncol. 2014 Aug;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8. Int J Clin Oncol. 2014. PMID: 24101215 Free article. Clinical Trial.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H. Toi M, et al. Among authors: hisamatsu k. Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10. Cancer Sci. 2011. PMID: 21231986 Free article.
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano H, Toi M. Takada M, et al. Among authors: hisamatsu k. Breast. 2012 Feb;21(1):40-5. doi: 10.1016/j.breast.2011.07.015. Epub 2011 Aug 19. Breast. 2012. PMID: 21855342 Free article.
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Ueno T, et al. Among authors: hisamatsu k. BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9. BMC Cancer. 2016. PMID: 26984766 Free PMC article. Clinical Trial.
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group. Iwata H, et al. Among authors: hisamatsu k. Breast Cancer. 2005;12(2):99-103. doi: 10.2325/jbcs.12.99. Breast Cancer. 2005. PMID: 15858439 Free article. Clinical Trial.
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Ueno T, et al. Among authors: hisamatsu k. ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018. ESMO Open. 2018. PMID: 29531841 Free PMC article.
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M. Ohno S, et al. Among authors: hisamatsu k. Breast Cancer Res Treat. 2013 Nov;142(1):69-80. doi: 10.1007/s10549-013-2691-y. Breast Cancer Res Treat. 2013. PMID: 24122389 Free PMC article. Clinical Trial.
[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)].
Masuda N, Toi M, Takatsuka Y, Nakamura S, Iwata H, Ohno S, Kuroi K, Kusama M, Hisamatsu K, Yamazaki K, Eisei S, Sato Y, Kaise H, Kashiwaba M, Iwase H, Kurosumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group. Masuda N, et al. Among authors: hisamatsu k. Gan To Kagaku Ryoho. 2007 Oct;34(10):1609-15. Gan To Kagaku Ryoho. 2007. PMID: 17940375 Japanese.
176 results